1. US Food and Drug Administration. Draft guidance: Guidance for Industry Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling http:www.fda.govcderGuidance6695dft.htm http:www.fda.govcderguidanceindex.htmclinical20pharmacology http:www.fda.govCderdrugdrugInteractionsdefault.htm
2. Drug-drug interactions: study design, data analysis and implications for dosing recommendations;Huang;Clin Pharmacol Ther,2007
3. The need of multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study;Oo;J Clin Pharmacol
4. An open label study to determine how different durations of ketoconazole (ket) dosing inhibit cytochrome P450 3A4 (CYP3A4) as assessed by midazolam (MDZ) pharmacokinetics (PK);Friedman;Clin Pharmacol Ther,2008
5. Prolonged jaundice following ketoconazole-induced hepatic injury;Benson;Dig Dis Sci,1988